Andrew Cavey

Andrew Cavey, M.D., was appointed Global Program Head, Prostate Cancer for Advanced Accelerator Applications (AAA), a Novartis company, in September 2020. He is also a member of the Oncology Development Leadership Team at Novartis. Prior to joining AAA, Andrew served as Global Program Head, Benign Hematology, in the Hematology Development Unit of Novartis from 2017 to 2020, where he led the portfolio’s development and life cycle management activities. From 2015 to 2017, Andrew was the Cardio-Metabolic Business Unit Head in China for Novartis Pharmaceuticals and from 2012-2015, Strategic Assistant to the CEO. Prior to joining Novartis in 2012, Andrew was a consultant at McKinsey & Company from 2008 to 2012, and previously a diplomat in the British Foreign and Commonwealth Office from 2006 to 2007. From 2002 to 2006, Andrew worked as a physician in the United Kingdom’s National Health Service. He is a Member of the United Kingdom’s Royal College of Physicians and a Board member of the charity, Parkinson’s UK. Andrew holds his Medical and Masters in Physiological Sciences degrees from the University of Oxford, and a Master of Public Health from Harvard University.